Research programme: enterotoxigenic Escherichia coli vaccine - Sanofi Pasteur/US Naval Medical Research Center

Drug Profile

Research programme: enterotoxigenic Escherichia coli vaccine - Sanofi Pasteur/US Naval Medical Research Center

Alternative Names: Travelers diarrhea vaccine - Sanofi Pasteur/NMRC; Travellers diarrhoea vaccine - Sanofi Pasteur/US NMRC

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Naval Medical Research Center; sanofi pasteur
  • Developer Naval Medical Research Center; Sanofi Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Traveller's diarrhoea

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Traveller's-diarrhoea in USA
  • 12 Apr 2010 Preclinical trials in Traveller's diarrhoea in USA (unspecified route)
  • 12 Apr 2010 Sanofi Pasteur establishes CRADA with the US Naval Medical Research Center for the development of an enterotoxigenic Escherichia coli vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top